People say to write what you know and Ed Tobias knows about MS. He’s lived with the illness since 1980, when he was 32 years old. Ed’s a retired, award-winning broadcast journalist and his column combines his four decades of MS experiences with news and comments about the latest in the MS community. In addition to writing his column, Ed is one of the patient moderators on the MS News Today Facebook, Twitter, and Instagram sites. He’s also the author of “The Multiple Sclerosis Toolbox: Hints and Tips for Living with M.S.” Ed and his wife split their time between the Washington, D.C. suburbs and Florida’s Gulf Coast, trying to follow the sun.
This is my 823rd column for Multiple Sclerosis News Today. It is also my last. Over the past seven and a half years, I’ve written about multiple sclerosis (MS) fatigue and…
Read more
FDA Approves Kesimpta, B-cell Targeting Therapy for Relapsing MS The U.S. Food and Drug Administration’s approval of Kesimpta (ofatumumab) this month is a pretty big deal. Kesimpta is a once-a-month injectable disease-modifying therapy.
I’ve been walking with the Bioness L300 Go for about eight months, so it’s time to update everyone on how things are going. The L300 Go is a functional electrical stimulator (FES) that…
Ofatumumab Seen as Superior to Aubagio at Lowering Relapse Rates in Phase 3 Trials Ofatumumab is a cancer medication that’s awaiting approval by the U.S. Food and Drug Administration and the European Medicines…
The idea doesn’t seem very appealing to me, but a company is seeking approval from the U.S. Food and Drug Administration (FDA) for a product that might help people with MS walk better by…
Smoking and Epstein-Barr Virus Combine to Raise MS Risk, Study Says A number of studies over several years have demonstrated a likely link between the Epstein-Barr virus and MS. Of course, there’s no…
In early July, I wrote a column about Disability Pride Month. It’s not for me, I said. I questioned the word “pride” and asked whether we need a special month to advocate for…
Order Seen in Motor Skills Affected by MS, With Walking Taking First Hit Read this headline carefully. It reports that walking takes the “first hit,” but that doesn’t mean it’s the first MS…
Like others these days, I’m worried about COVID-19. In fact, I’m probably more worried than some. I’m old, I have MS, and I’ve been treated with the disease-modifying therapy Lemtrada (alemtuzumab) —…
Ketamine May Help Treat MS-related Fatigue, Small Pilot Trial Suggests I’m tired — I mean really bushed. Today, despite my daily dose of modafinil, I have to sit and think, “What was I…
Do you ever wake up in the middle of the night thinking strange thoughts about your MS and your dog? I did the other night. I’ve written about Joey, my cocker spaniel, a couple…
MSAA Opens ‘COVID-19 and MS Pathfinder’ Online Informative Platform Information about MS and COVID-19 is dynamic and regularly changing. This has been particularly true about how to handle disease-modifying therapies (DMTs). The website…
I’d just gotten out of bed the other morning and was headed to the bathroom using just one cane when I tried to step over a dog toy on the floor. I went down…
B-Cells Infected by Epstein-Barr Virus Linked to MS Relapse Risk in Study I usually steer clear of mouse studies. Mice lie and monkeys exaggerate, some researchers say. But this is another piece to…
July is Disability Pride Month. Now, don’t slam me right away for writing this, but I don’t think we need a month highlighting disability pride — just like I don’t think we need a…
PROTXX, University of Alberta Collaborate to Develop Remote Healthcare Platform for MS Patients As more and more neurologists turn to telemedicine for routine patient visits, I expect we’ll see more of the type…
NICE Does Not Favor Adding Mayzent to NHS England for Active SPMS Currently, the only disease-modifying therapy approved for use in the National Health Service is Betaferon (interferon beta-1b). That’s a 20-year-old treatment…
It’s been a few weeks since I’ve written about the impact that COVID-19 is having on people with MS. Since then, the picture has changed — not a lot, but enough for the…
Gilenya May Help Control Severe Respiratory Disease in COVID-19 This story caught my eye, but not because of the possibility that Gilenya may help someone recover from COVID-19. It caught my eye because…
A couple new mobile apps for people with MS have caught my attention. Icompanion is among the best symptom and treatment trackers I’ve found. BelongMS combines patient forums with the ability to…
Note: A story mentioned in this column, “Prime Signs Agreement With EMD Serono to Improve Mavenclad’s Cost-benefit Value,” was updated on June 15, 2020,…
Get regular updates to your inbox.
